TABLE 2

Comparison of pharmacokinetic parameters for anticancer drugs in wild-type and BCN mice

Drugs	Parameter	Units	WT	BCN	P value^{^a}
Cyclophosphamide	AUC_last	min*μg/ml	1659 ± 287	2589 ± 367	n.s.
	AUC_infin	min*μg/ml	1678 ± 641	2605 ± 821	n.s.
	C_max	μg/ml	17.0 ± 1.6	26.4 ± 2.7	*
	Clearance	ml/min per kilogram	135 ± 24.5	82.5 ± 9.9	n.s.
	Terminal half-life	min	42.5 ± 5.2	60.1 ± 2.5	*
Paclitaxel	AUC_last	min*μg/ml	318 ± 67.4	292 ± 67.4	n.s.
	AUC_infin	min*μg/ml	381 ± 213	349 ± 168	n.s.
	C_max	μg/ml	1.9 ± 0.40	2.2 ± 0.54	n.s.
	Clearance	ml/min per kilogram	51.2 ± 13.1	58.7 ± 20.1	n.s.
	Terminal half-life	min	148 ± 37.1	149 ± 24.9	n.s.
Tamoxifen	AUC_last	min*μg/ml	16.4 ± 6.2	77.2 ± 16.5	***
Tamoxifen	C_max	μg/ml	0.06 ± 0.03	0.2 ± 0.04	***
Anastrozole	AUC_last	min*μg/ml	22.4 ± 14.5	48.1 ± 10.0	*
	AUC_infin	min*μg/ml	22.6 ± 14.5	50.4 ± 11.1	*
	C_max	μg/ml	0.19 ± 0.13	0.23 ± 0.04	n.s.
	Clearance	ml/min per kilogram	29.3 ± 36.6	6.2 ± 1.4	*
	Terminal half-life	min	62.3 ± 6.7	101 ± 18.1	**
Gefitinib	AUC_last	min*μg/ml	162 ± 26.9	145 ± 62.1	n.s.
	C_max	μg/ml	0.5 ± 0.04	0.5 ± 0.20	n.s.

n.s., Not significant.
↵a P values relate to comparison between BCN and wild-type groups; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.